Working… Menu

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers (PREVLAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03515538
Recruitment Status : Completed
First Posted : May 3, 2018
Last Update Posted : January 11, 2021
Prothex Pharma, Inc.
Information provided by (Responsible Party):
EpicentRx, Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : October 22, 2019
Actual Study Completion Date : October 8, 2020